FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102032555> ?p ?o ?g. }

• W2102032555 endingPage "1388" @default.
• W2102032555 startingPage "1380" @default.
• W2102032555 abstract "Background The role of locoregional treatment in women with metastatic breast cancer at first presentation is unclear. Preclinical evidence suggests that such treatment might help the growth of metastatic disease, whereas many retrospective analyses in clinical cohorts have suggested a favourable effect of locoregional treatment in these patients. We aimed to compare the effect of locoregional treatment with no treatment on outcome in women with metastatic breast cancer at initial presentation. Methods In this open-label, randomised controlled trial, we recruited previously untreated patients (≤65 years of age with an estimated remaining life expectancy of at least 1 year) presenting with de-novo metastatic breast cancer from Tata Memorial Centre, Mumbai, India. Patients were randomly assigned (1:1) to receive locoregional treatment directed at their primary breast tumour and axillary lymph nodes, or no locoregional treatment, by a computer-generated block randomisation sequence (block size of four). Randomisation was stratified by site of distant metastases, number of metastatic lesions, and hormone receptor status. Patients with resectable primary tumour in the breast that could be treated with endocrine therapy were randomly assigned upfront, whereas those with an unresectable primary tumour were planned for chemotherapy before randomisation. Of the patients who had chemotherapy before randomisation, we randomly assigned patients who had an objective tumour response after six to eight cycles of chemotherapy. The primary endpoint was overall survival analysed by intention to treat. This study is registered with ClinicalTrials.gov, NCT00193778. Findings Between Feb 7, 2005, and Jan 18, 2013, of the 716 women presenting with de-novo metastatic breast cancer, we randomly assigned 350 patients: 173 to locoregional treatment and 177 to no locoregional treatment. At data cut-off of Nov 1, 2013, median follow-up was 23 months (IQR 12·2–38·7) with 235 deaths (locoregional treatment n=118, no locoregional treatment n=117). Median overall survival was 19·2 months (95% CI 15·98–22·46) in the locoregional treatment group and 20·5 months (16·96–23·98) in the no-locoregional treatment group (HR 1·04, 95% CI 0·81–1·34; p=0·79), and the corresponding 2-year overall survival was 41·9% (95% CI 33·9–49·7) in the locoregional treatment group and 43·0% (35·2–50·8) in the no locoregional treatment group. The only adverse event noted was wound infection related to surgery in one patient in the locoregional treatment group. Interpretation There is no evidence to suggest that locoregional treatment of the primary tumour affects overall survival in patients with metastatic breast cancer at initial presentation who have responded to front-line chemotherapy, and this procedure should not be part of routine practice. Funding Department of Atomic Energy, Government of India." @default.
• W2102032555 created "2016-06-24" @default.
• W2102032555 creator A5022310549 @default.
• W2102032555 creator A5042634197 @default.
• W2102032555 creator A5048611916 @default.
• W2102032555 creator A5050720436 @default.
• W2102032555 creator A5058903725 @default.
• W2102032555 creator A5061619941 @default.
• W2102032555 creator A5066523060 @default.
• W2102032555 creator A5067497872 @default.
• W2102032555 creator A5075196057 @default.
• W2102032555 date "2015-10-01" @default.
• W2102032555 modified "2023-10-14" @default.
• W2102032555 title "Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial" @default.
• W2102032555 cites W1511271751 @default.
• W2102032555 cites W1991082809 @default.
• W2102032555 cites W1991164526 @default.
• W2102032555 cites W1998045778 @default.
• W2102032555 cites W2000553697 @default.
• W2102032555 cites W2002321581 @default.
• W2102032555 cites W2004976199 @default.
• W2102032555 cites W2011827457 @default.
• W2102032555 cites W2025718854 @default.
• W2102032555 cites W2038252533 @default.
• W2102032555 cites W2041560945 @default.
• W2102032555 cites W2041715804 @default.
• W2102032555 cites W2046002819 @default.
• W2102032555 cites W2056109144 @default.
• W2102032555 cites W2059983781 @default.
• W2102032555 cites W2068230391 @default.
• W2102032555 cites W2080801254 @default.
• W2102032555 cites W2090088216 @default.
• W2102032555 cites W2103878461 @default.
• W2102032555 cites W2104907399 @default.
• W2102032555 cites W2105937199 @default.
• W2102032555 cites W2116356654 @default.
• W2102032555 cites W2116661424 @default.
• W2102032555 cites W2118183402 @default.
• W2102032555 cites W2125896378 @default.
• W2102032555 cites W2127569660 @default.
• W2102032555 cites W2127940293 @default.
• W2102032555 cites W2152752482 @default.
• W2102032555 doi "https://doi.org/10.1016/s1470-2045(15)00135-7" @default.
• W2102032555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26363985" @default.
• W2102032555 hasPublicationYear "2015" @default.
• W2102032555 type Work @default.
• W2102032555 sameAs 2102032555 @default.
• W2102032555 citedByCount "384" @default.
• W2102032555 countsByYear W21020325552015 @default.
• W2102032555 countsByYear W21020325552016 @default.
• W2102032555 countsByYear W21020325552017 @default.
• W2102032555 countsByYear W21020325552018 @default.
• W2102032555 countsByYear W21020325552019 @default.
• W2102032555 countsByYear W21020325552020 @default.
• W2102032555 countsByYear W21020325552021 @default.
• W2102032555 countsByYear W21020325552022 @default.
• W2102032555 countsByYear W21020325552023 @default.
• W2102032555 crossrefType "journal-article" @default.
• W2102032555 hasAuthorship W2102032555A5022310549 @default.
• W2102032555 hasAuthorship W2102032555A5042634197 @default.
• W2102032555 hasAuthorship W2102032555A5048611916 @default.
• W2102032555 hasAuthorship W2102032555A5050720436 @default.
• W2102032555 hasAuthorship W2102032555A5058903725 @default.
• W2102032555 hasAuthorship W2102032555A5061619941 @default.
• W2102032555 hasAuthorship W2102032555A5066523060 @default.
• W2102032555 hasAuthorship W2102032555A5067497872 @default.
• W2102032555 hasAuthorship W2102032555A5075196057 @default.
• W2102032555 hasConcept C121608353 @default.
• W2102032555 hasConcept C126322002 @default.
• W2102032555 hasConcept C141071460 @default.
• W2102032555 hasConcept C143998085 @default.
• W2102032555 hasConcept C168563851 @default.
• W2102032555 hasConcept C203092338 @default.
• W2102032555 hasConcept C2775930923 @default.
• W2102032555 hasConcept C2776694085 @default.
• W2102032555 hasConcept C2777649267 @default.
• W2102032555 hasConcept C530470458 @default.
• W2102032555 hasConcept C71924100 @default.
• W2102032555 hasConceptScore W2102032555C121608353 @default.
• W2102032555 hasConceptScore W2102032555C126322002 @default.
• W2102032555 hasConceptScore W2102032555C141071460 @default.
• W2102032555 hasConceptScore W2102032555C143998085 @default.
• W2102032555 hasConceptScore W2102032555C168563851 @default.
• W2102032555 hasConceptScore W2102032555C203092338 @default.
• W2102032555 hasConceptScore W2102032555C2775930923 @default.
• W2102032555 hasConceptScore W2102032555C2776694085 @default.
• W2102032555 hasConceptScore W2102032555C2777649267 @default.
• W2102032555 hasConceptScore W2102032555C530470458 @default.
• W2102032555 hasConceptScore W2102032555C71924100 @default.
• W2102032555 hasIssue "13" @default.
• W2102032555 hasLocation W21020325551 @default.
• W2102032555 hasLocation W21020325552 @default.
• W2102032555 hasOpenAccess W2102032555 @default.
• W2102032555 hasPrimaryLocation W21020325551 @default.
• W2102032555 hasRelatedWork W1905072147 @default.
• W2102032555 hasRelatedWork W1997105855 @default.
• W2102032555 hasRelatedWork W2013223288 @default.
• W2102032555 hasRelatedWork W2117125345 @default.

• next